The effect of pioglitazone in patients with diabetes and asthma

The effect of pioglitazone in improving respiratory and inflammatory markers in patients with diabtes and asthma- clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016050827785N1

Enrollment

Registered

2016-12-03

Start date

2015-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes and Asthma. Insulin-dependent diabetes mellitus, Non-insulin-dependent diabetes mellitus, Malnutrition-related diabetes mellitus, Other specified diabetes mellitus, Unspecified diabetes mellitus, Asthma, unspecified

Interventions

Intervention(Pioglitazone, 30mg/day, For three months).

Treatment - Drugs

Intervention(Pioglitazone, 30mg/day, For three months)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: aged between 18 and 75 years,diagnosed asthma for at least one year, HbA1C between 8-9, methacholine or bronchodilator positive tests, treated with inhaled corticosteroid for at least three months with or without long-acting inhaled bronchodilator,no other diseases in radiography. Exclusion criteria: hypersensitivity to pioglitazone, receiving oral steroids, smoking during the past three months, respiratory infections within a month before the start of the study , history of pulmonary diseases besides asthma, more than 2+ edema, heart failure, osteopenia or osteoporosis (T-score <-1).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FEV1. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Second.;CRP-Hs. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/l.;NO. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Second.;Leptin. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: ng/ml.;Ig E. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: ng/ml.;FBS. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;2hpp. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;A1C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Percent.;FEV1/FVC. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Percent.	—

Measure

Time frame

FEV1. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Second.;CRP-Hs. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/l.;NO. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Second.;Leptin. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: ng/ml.;Ig E. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: ng/ml.;FBS. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;2hpp. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Mg/dl.;A1C. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Percent.;FEV1/FVC. Timepoint: At baseline and three months after the initiation of trial. Method of measurement: Percent.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReihane Azizi

Yazd Diabetes Research Center

Raihne.Azizi@yahoo.com+98 35 3728 0217

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026